ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
17.038
0.37%
Brent Oil
80.885
0.10%
Bitcoin
69,004.72
1.85%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE
  6. Merck & Co Inc (0QAH)

  7. Merck & Co Inc (0QAH) Noticias

0QAH

Merck & (0QAH)

Merck & Co Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:0QAH
FechaHoraFuenteTítuloSímboloCompañía
29/05/202408:22Alliance NewsAlliance NewsMerck & Co enhances ophthalmology portfolio with EyeBio acquisitionLSE:0QAHMerck & Co Inc
25/04/202406:13Alliance NewsAlliance NewsMerck & Co raises annual outlook thanks to first quarter boostLSE:0QAHMerck & Co Inc
15/03/202410:23Alliance NewsAlliance NewsIN BRIEF: Merck hails positive data on cervical cancer drug, KeytrudaLSE:0QAHMerck & Co Inc
20/02/202415:15Alliance NewsAlliance NewsMerck and Astellas drugs get priority review in US and JapanLSE:0QAHMerck & Co Inc
01/02/202406:57Alliance NewsAlliance NewsTOP NEWS: Merck books 2023 growth despite gefapixant rejection hitLSE:0QAHMerck & Co Inc
19/01/202405:29Alliance NewsAlliance NewsIN BRIEF: Arix Bioscience eyes USD19 million return from Harpoon saleLSE:0QAHMerck & Co Inc
08/01/202408:20Alliance NewsAlliance NewsMerck to buy Harpoon Therapeutics for about USD680 millionLSE:0QAHMerck & Co Inc
18/12/202305:04Alliance NewsAlliance NewsAstellas, Merck, Pfizer celebrate US approval for Keytruda plus PadcevLSE:0QAHMerck & Co Inc
15/12/202302:41Alliance NewsAlliance NewsMerck gets US FDA nod for Welireg, as trial with Moderna bears fruitLSE:0QAHMerck & Co Inc
11/12/202311:56Alliance NewsAlliance NewsMerck reports mixed updates for cancer treatment, KeytrudaLSE:0QAHMerck & Co Inc
26/10/202306:17Alliance NewsAlliance NewsTOP NEWS: Merck hails Daiichi Sankyo partnership but will take chargeLSE:0QAHMerck & Co Inc
20/10/202300:06Alliance NewsAlliance NewsTOP NEWS: Daiichi Sankyo soars on USD22 billion Merck cancer drug dealLSE:0QAHMerck & Co Inc
03/10/202311:00Alliance NewsAlliance NewsDrugmakers agree to US government price talks amid pushbackLSE:0QAHMerck & Co Inc
24/08/202310:24Alliance NewsAlliance NewsUPDATE: AstraZeneca, Merck & Co say Lynparza approved in JapanLSE:0QAHMerck & Co Inc
01/08/202306:49Alliance NewsAlliance NewsMerck & Co second quarter revenue up; profit falls acquisition costsLSE:0QAHMerck & Co Inc
16/06/202307:09Alliance NewsAlliance NewsMerck says latest trial data shows Keytruda meets survival endpointLSE:0QAHMerck & Co Inc
01/06/202307:44Alliance NewsAlliance NewsMerck and Astra's Lynparza prostate cancer treatment gets US approvalLSE:0QAHMerck & Co Inc
01/05/202306:35Alliance NewsAlliance NewsAstraZeneca "disappointed" with US ODAC's guidance on LynparzaLSE:0QAHMerck & Co Inc
27/04/202306:49Alliance NewsAlliance NewsMerck & Co beats on first-quarter revenue and hails "advancements"LSE:0QAHMerck & Co Inc
10/03/202306:31Alliance NewsAlliance NewsMerck's Keytruda combination sees positive results in cancer trialLSE:0QAHMerck & Co Inc
02/03/202311:20Alliance NewsAlliance NewsUS FDA to discuss AstraZeneca and Merck's Lynparza cancer drug comboLSE:0QAHMerck & Co Inc
24/02/202306:48Alliance NewsAlliance NewsIN BRIEF: EU refuses marketing recommendation for Merck's LagevrioLSE:0QAHMerck & Co Inc
02/02/202307:08Alliance NewsAlliance NewsTOP NEWS: Merck & Co annual net profit up but drops in fourth-quarterLSE:0QAHMerck & Co Inc
30/01/202310:35Alliance NewsAlliance NewsDaiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatmentLSE:0QAHMerck & Co Inc
21/12/202203:16Alliance NewsAlliance NewsAstraZeneca wins two new approvals in EU for cancer drugsLSE:0QAHMerck & Co Inc
20/12/202212:09Alliance NewsAlliance NewsFDA accepts Astellas, Seagen and Merck's combo for priority reviewLSE:0QAHMerck & Co Inc
15/12/202202:37Alliance NewsAlliance NewsAstraZeneca and Merck receive US FDA extension for Lynparza reviewLSE:0QAHMerck & Co Inc
22/11/202211:18Alliance NewsAlliance NewsIN BRIEF: Merck's Keytruda sees positive topline results in trialLSE:0QAHMerck & Co Inc
21/11/202206:53Alliance NewsAlliance NewsMerck buys biopharmaceutical firm Imago BioSciences for USD1.4 billionLSE:0QAHMerck & Co Inc
27/10/202208:29Alliance NewsAlliance NewsTOP NEWS: Merck & Co 3rd-quarter sales up; profit slips as costs riseLSE:0QAHMerck & Co Inc
 Showing the most relevant articles for your search:LSE:0QAH

Su Consulta Reciente

COIN
BTCUSD
Bitcoin
NYSE
MCD
McDonalds
CCOM
US500
US 500
NASDAQ
GOOGL
Alphabet
USOTC
BASFY
BASF (QX)
NYSE
KO
Coca Cola
NYSE
BAC
Bank of America
NYSE
JPM
JP Morgan Chase
NASDAQ
AAPL
Apple
FX
USDMXN
US Dollar vs MXN
NASDAQ
TSLA
Tesla
AMEX
XLF
Financial Select Sector
NYSE
DIS
Walt Disney
NYSE
AXP
American Express
NASDAQ
AMZN
Amazon.com
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados